U.S. to purchase at least 100K doses of Lilly antibody cocktail

The federal government has agreed to purchase at least 100,000 doses of the combination monoclonal antibody therapy bamlanivimab and etesevimab, Eli Lilly and Company announced Friday.

The Food and Drug Administration last month issued an emergency use authorization to administer the antibodies together to patients with mild-to-moderate COVID-19 at high risk for progressing to severe disease but not hospitalized or on oxygen therapy.